Ligand Pharmaceuticals has acquired Vernalis for $42.3m, giving the former access to a portfolio of eight fully funded programmes, as well as a 70-person research and development (R&D) team located in Cambridge, England.

Ligand also received a compound library with additional and early stage programmes in central nervous system (CNS), oncology and various other areas.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

MTS Securities and finnCap were the financial advisers and Latham Watkins was the legal adviser to Ligand for the transaction.

Based in the US, Ligand Pharmaceuticals is a biopharmaceutical company focused on the development and acquisition of drug development technologies, while Vernalis is a pharmaceutical company based in the UK.

The US Department of Justice (DOJ) has cleared CVS Health’s proposal to acquire Aetna.

The acquisition is expected to close by the fourth quarter of 2018, subject to approvals from the state.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The DOJ approval comes with a condition for Aetna to divest its stand-alone prescription drug business Medicare Part D.

Based in the US, CVS Health is a pharmacy and healthcare company, while Aetna is a healthcare company offering healthcare insurance plans along with other medical and pharmaceutical services.

“The US Department of Justice (DOJ) has cleared CVS Health’s proposal to acquire Aetna.”

Mundipharma has announced the acquisition of Cinfa Biotech strengthening its position in the biosimilars market.

The acquisition has provided the company with immediate access to Pelmeg® (B12019), a biosimilar to Neulasta® (pegfilgrastim) indicated for the treatment of chemotherapy-induced neutropenia.

Pelmeg® is under review in the European Union and has been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use in September 2018.

Based in the UK, Mundipharma is a pharmaceutical company focused on several therapeutic areas including respiratory, oncology and biosimilars, while Cinfa Biotech is a biosimilars developer based in Spain.

Corium International has signed a merger agreement valued up to $504m with Gurnet Point Capital (GPC), under which the latter will acquire the company.

Corium will receive $12.50 a share in cash from GPC, upon completion of the transaction. It is also entitled to receive a Contingent Value Right (CVR) of $0.50 a share upon approval of its lead product candidate Corplex Donepezil, which is indicated for the treatment of Alzheimer’s disease.

Based in the US, Corium is a biopharmaceutical company focused on the development of novel transdermal healthcare solutions, while Gurnet Point Capital, also based in the US, is a healthcare fund company.